Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11's Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Stock Information for Medicenna Therapeutics Corp.

Loading

Please wait while we load your information from QuoteMedia.